Rates of ocular adverse effects under ranibizumab and bevacizumab/RCTs
| Endophthalmitis (%) | Uveitis (%) | Retinal detachment (%) | Retinal tear (%) | Lens damage (traumatic) (%) | Vitreous haemorrhage (%) | |||||||||||||
| Ranibizumab | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT | 0.3 mg | 0.5 mg | PDT |
| ANCHOR 200912 | 0.0 | 2.1 | 0.0 | 0.0 | 0.7 | 0.0 | 1.5 | 0.0 | 0.7 | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 |
| Ranibizumab | Sham | Sham | Sham | Sham | Sham | Sham | ||||||||||||
| MARINA 20066 | 0.8 | 1.3 | 0.0 | 1.3 | 1.3 | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 0.4 | 0.4 | 0.8 |
| Ranibizumab PIER 200813 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Ranibizumab | 0.3/0.5 mg | UC | UC | UC | 0.3/0.5 | UC | UC | UC | ||||||||||
| Heier 200614 | 1.6* | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9* | 0.0 | Nr | Nr | Nr | 8.0 | 3.6 | 0.0 | ||
| Bevacizumab | 2.5 mg | PDT | 2.5 mg | PDT | 2.5 mg | PDT | 2.5 mg | PDT | 2.5 mg | PDT | 2.5 mg | PDT | ||||||
| Bashshur 200721 | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | ||||||
| Bevacizumab | 1.25 mg | PDT | 1.25 mg | PDT | 1.25 mg | PDT | 1.25 mg | PDT | 1.25 mg | PDT | 1.25 mg | PDT | ||||||
| Lazic 200722 | Nr | Nr | Nr | Nr | Nr | Nr | 5.5 | 0.0 | Nr | Nr | Nr | Nr | ||||||
| Bevacizumab | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | ||||||
| Hahn 200723 | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | Nr | ||||||
| Bevacizumab | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | 1.0 mg | PDT+ivTC | ||||||
| Sacu 200924 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Nr | Nr | 0 | 0 | Nr | Nr | ||||||
↵* After 3 months (part I of the study).
Nr, not reported; UC, usual care; IvTC, intravitreal triamcinolone.